Medtronic cardiovascular organic growth in fiscal 2027
Short Answer
The model sees Medtronic's fiscal 2027 cardiovascular organic growth Above 6% at 20.0% probability versus the market's 0.0%, driven by management's anticipation of growth broadly in line with fiscal 2026's 10.1% performance.
1. Market Behavior & Drivers
This market's price action is defined by a single, sharp upward revision. The contract opened at a 1.0% probability and subsequently moved to its current price of 88.0%. With only two data points recorded, this constitutes the entirety of the market's price history. There is no trading volume, indicating the price change reflects a shift in the standing offer rather than a consensus formed through transactions.
The price surge to 88.0% appears directly linked to Medtronic's guidance for company-wide organic revenue growth, which was set at a range of 6.75% to 7.25% for fiscal year 2027. Although the company did not release a specific growth target for its cardiovascular segment, the market price suggests participants are using the broader corporate forecast as a strong proxy. The 88.0% probability implies a high degree of confidence that the cardiovascular segment's performance will meet the market's resolution criteria.
Given the complete absence of trading volume, technical analysis is limited. There are no established support or resistance levels, and the price reflects the sentiment of a single or small number of participants willing to offer contracts at this level. The market's conviction remains untested by actual trading activity. The current price indicates a strong bullish outlook on the segment's growth, anchored entirely to the company-level financial guidance.
- Medtronic anticipates Cardiovascular organic growth broadly in line with prior year's 10.1%.
- Strong momentum in Cardiac Ablation Solutions and Rhythm Management supports this outlook.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 10% | 41.0% | 20.0% | Market higher by 21.0pp |
| Above 11% | 0.0% | 20.0% | Model higher by 20.0pp |
| Above 6% | 0.0% | 20.0% | Model higher by 20.0pp |
| Above 7% | 0.0% | 20.0% | Model higher by 20.0pp |
| Above 8% | 0.0% | 20.0% | Model higher by 20.0pp |
Current Context
Medtronic provides company-wide FY2027 organic growth guidance, not cardiovascular-specific. For fiscal year 2027, Medtronic has guided company-wide organic revenue growth to a range of 6.75% to 7.25% [^][^][^][^]. There is no specific sub-portfolio guidance for the Cardiovascular segment's organic growth percentage disclosed for FY2027 [^][^]. In comparison, the Cardiovascular portfolio achieved 10.1% organic growth in fiscal year 2026 [^][^][^].
FY2027 company guidance incorporates specific operational and market factors. The projected FY2027 company-wide growth includes the impact of a 53rd week in the first quarter and the full-year revenue from the Diabetes business, while excluding foreign currency effects and "Other" revenue [^][^][^]. Management expects approximately 11.5% to 12.0% organic growth for the total company in the first quarter of fiscal 2027 [^][^]. Other financial assumptions for FY2027 include an anticipated $250 million impact from tariffs, $150 million added from mergers and acquisitions, and diluted non-GAAP EPS growth projected between 6.7% and 8.5%, targeting $5.90 to $6.00 [^][^]. Medtronic is scheduled to report its first quarter fiscal year 2027 results on September 1, 2026 [^][^]. Medtronic also announced an expanded CE Mark indication for its Affera Mapping and Ablation System with Sphere-9 Catheter on August 6, 2026, to treat ventricular arrhythmias [^][^]. This development supports international growth for cardiac ablation technology and holds FDA Breakthrough Device Designation, with the Sphere VT pivotal trial actively enrolling [^][^].
Analyst commentary reflects overall growth, but segment-specific data remains undisclosed. Recent market articles have maintained a constructive view on Medtronic's growth outlook, referencing an approximate 7% FY2027 organic revenue growth for the company and noting a strategic restructuring toward higher-margin portfolios, including cardiovascular and neuroscience [^][^][^]. However, these are external analyst or media observations and do not represent company-issued cardiovascular Key Performance Indicators for FY2027 [^][^][^]. The provided evidence does not contain a standalone FY2027 organic revenue growth target specifically for Medtronic's cardiovascular segment.
2. Price Chart
Historical Price (Probability)
Outcome probability
Date
3. Market Data
Contract Snapshot
For the "Medtronic cardiovascular organic growth in fiscal 2027 - Above 9%" market:
A YES resolution triggers if Medtronic's cardiovascular organic growth in fiscal 2027 is greater than 9%. Conversely, a NO resolution triggers if the growth is 9% or less. Trading for this market ends on June 2, 4:00 PM EDT, with a maximum payout date of August 31, 2027. No special settlement conditions are detailed in the provided content.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 10% | $0.47 | $0.63 | 41% |
| Above 11% | $0.25 | $0.85 | 0% |
| Above 6% | $0.99 | $0.11 | 0% |
| Above 7% | $0.95 | $0.15 | 0% |
| Above 8% | $0.85 | $0.25 | 0% |
| Above 9% | $0.65 | $0.45 | 0% |
Market Discussion
Medtronic has announced its Cardiovascular (CV) segment's organic revenue growth guidance for fiscal 2027 is approximately 5% [^][^][^][^][^][^][^]. This guidance is distinct from the company's broader enterprise organic revenue growth guidance of 6.75% to 7.25% for FY2027 [^][^][^][^][^][^][^][^]. While the CV portfolio achieved 10.1% organic growth in fiscal 2026, driven by Cardiac Ablation Solutions, a prediction market is tracking fiscal 2027 performance against a threshold of above 6% [^][^][^][^][^].
4. Trust Index
Company-reported metric: finance and investor relations know the number before the earnings release
Integrity risk· Information exposure
How it adds up
Integrity80% of score74Good
Info fairness is low (40), but Integrity averages all three scores, so the other two pull it up. Only a critically low score would cap the total.
Trade quality20% of score48High Risk
Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.
Trust score69Caution
Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index
Trust profile
Integrity4 screens run · 3 don't apply · 3 awaiting data
5. What are the key product pipelines and market dynamics expected to drive or hinder Medtronic's Cardiovascular organic growth in fiscal 2027?
| Medtronic CAS Growth | More than twice the market rate into FY27 (Medtronic projects) [^][^][^][^][^][^][^] |
|---|---|
| CAS Market Growth | Mid- to high-teens (Medtronic management expectation) [^][^][^][^][^][^][^] |
| Tariff Impacts FY27 | Approximately $250 million (Medtronic projection) [^][^][^][^] |
Medtronic expects its Cardiovascular organic growth to mirror prior year performance. Medtronic projects its Cardiovascular portfolio's organic growth in fiscal 2027 to align generally with its fiscal 2026 results [^][^][^][^][^][^][^][^][^]. This anticipated growth is primarily driven by strong momentum in Cardiac Ablation Solutions (CAS), Cardiac Rhythm Management (CRM), and the expanding adoption of renal denervation therapies [^][^][^][^][^][^][^][^][^]. The company did not provide a specific numerical organic growth range for the segment for FY27, suggesting some level of uncertainty regarding the exact magnitude of growth [^][^][^][^][^][^][^][^].
Several key product pipelines are set to significantly boost growth. Leading growth contributors include the Cardiac Ablation Solutions (CAS) segment, which is projected to grow more than twice the overall market rate into fiscal 2027, with the CAS market itself forecast to expand in the mid- to high-teens [^][^][^][^][^][^][^]. Robust mid-single-digit growth is also anticipated in Cardiac Rhythm Management, propelled by innovations such as Micra leadless pacemakers and OmniaSecure leads [^][^][^][^][^][^][^][^][^][^][^]. Furthermore, the ramp-up of the Symplicity renal denervation therapy and the expanded CE Mark indication for the Affera™ Mapping and Ablation System as of August 6, 2026, are expected to provide additional momentum [^][^][^][^][^][^][^][^][^][^][^][^]. Strategic restructuring of the portfolio and focused tuck-in mergers and acquisitions are also planned to enhance growth and address competitive dynamics [^][^][^][^].
However, significant financial and market headwinds will impede growth. Despite these positive drivers, Medtronic's Cardiovascular organic growth in fiscal 2027 faces several hindering factors. These include an estimated $250 million impact from tariffs and a 1-point headwind stemming from increased fuel and transportation costs [^][^][^][^]. The Structural Heart segment is being managed with prudence, indicating a less aggressive acceleration in this area [^][^][^][^][^][^][^][^][^][^][^]. Additionally, corporate-level challenges such as higher interest and tax expenses are also expected to impact overall performance [^][^][^][^][^][^][^][^][^][^][^].
6. What is the consensus among financial analysts for Medtronic's Cardiovascular segment organic revenue growth in fiscal 2027?
| FY26 Cardiovascular Organic Growth | 10.1% [^][^][^][^][^][^][^] |
|---|---|
| FY27 Cardiovascular Organic Growth Expectation | Roughly flat to FY26 (approx. 10.1%) [^][^][^][^][^][^][^][^] |
| Q1 FY27 Cardiovascular Organic Growth Projection | 5% to 8% [^] |
Financial analysts lack an explicit consensus for Medtronic's FY27 Cardiovascular growth. There is no explicitly published numeric consensus among financial analysts regarding Medtronic's Cardiovascular segment organic revenue growth in fiscal 2027 [^][^][^][^][^][^]. However, Medtronic management has indicated expectations for the Cardiovascular segment's fiscal 2027 performance to be broadly in line with its fiscal 2026 results [^][^][^].
Management suggests FY27 Cardiovascular growth will align with FY26's performance. The Cardiovascular segment achieved 10.1% organic growth in fiscal year 2026 [^][^][^][^][^][^][^]. For fiscal 2027, management commentary described the business as growing at "about the same pace," with performance that is "pretty much in line" and showing "strong continuation" [^][^][^][^][^][^][^][^]. Based on this guidance language, the closest supported interpretation indicates that FY27 Cardiovascular organic growth is expected to be roughly flat compared to FY26's 10.1% organic growth [^][^][^][^][^][^][^][^].
Analysts project 5-8% Q1 FY27 Cardiovascular growth driven by PFA. Separately, market analysts have projected organic growth for the Cardiovascular segment in the first quarter of fiscal 2027 to be in the range of 5% to 8%, with the ramp-up of Pulse Field Ablation (PFA) anticipated as a key driver [^].
7. How does Medtronic's recent Cardiovascular organic growth compare to its primary competitors, Boston Scientific and Abbott Laboratories?
| Medtronic CV FY26 Organic Revenue Growth | 9.3% [^][^][^] |
|---|---|
| Medtronic CV FY27 Performance Expectation | Broadly in line with FY26 [^][^][^] |
| Boston Scientific FY26 Organic Sales Guidance | 5-6% [^] |
Medtronic's Cardiovascular segment posted robust growth and anticipates continued strength. The company's Cardiovascular segment achieved 10.1% organic revenue growth in the fourth quarter of fiscal year 2026, contributing to a 9.3% organic growth for the full fiscal year 2026 [^][^][^]. For fiscal year 2027, Medtronic projects its company-wide organic revenue growth to be between 6.75% and 7.25%, with the Cardiovascular segment expected to perform broadly in line with its strong fiscal 2026 results [^][^][^].
Competitors Boston Scientific and Abbott presented varied 2026 growth outlooks. Boston Scientific adjusted its 2026 organic sales growth guidance downward to a range of 5-6% from an earlier forecast of 6.5-8%, attributing this change to reduced demand for WATCHMAN devices and market share losses within electrophysiology [^]. Abbott Laboratories, another significant competitor, maintained its full-year 2026 comparable sales growth guidance for its overall business at 6.5% to 7.5%, noting strong growth in specific medical device areas such as electrophysiology during Q2 2026 [^]. However, specific fiscal year 2027 organic growth forecasts for the cardiovascular segments of Boston Scientific or Abbott Laboratories were not available in the provided information.
8. When and in which SEC filing will Medtronic officially report the final Cardiovascular organic revenue growth figure for fiscal 2027?
| Reporting Document | Form 10-K with the SEC [^] |
|---|---|
| Reporting Window | Within 60-90 days after fiscal year 2027 end [^] |
| Fiscal Year 2027 End | Late April 2027 [^] |
Medtronic will report final FY27 revenue growth in its Form 10-K. Medtronic is expected to officially report its final Cardiovascular organic revenue growth figure for fiscal year 2027 within its annual report on Form 10-K, filed with the SEC [^]. This filing is a requirement for public companies to officially disclose their audited annual financial results [^]. The Form 10-K serves as the official mechanism Medtronic uses to report its comprehensive financial results, including specific segment performance metrics like Cardiovascular organic revenue growth, to the SEC [^][^].
9. How might Medtronic's M&A strategy and recent acquisitions impact the Cardiovascular segment's FY2027 growth rate?
| Inorganic revenue growth contribution FY2027 | Approximately $150 million [^][^] |
|---|---|
| Enterprise-wide organic revenue growth guidance FY2027 | 6.75% to 7.25% [^][^][^] |
| M&A impact on organic growth metrics | Explicitly excluded [^][^] |
Medtronic’s acquisitions will add $150 million in inorganic revenue for FY2027. Medtronic's M&A activities, including the acquisition of CathWorks and an investment in Pulnovo Medical, are projected to contribute approximately $150 million to inorganic revenue growth in fiscal year 2027 [^][^]. These contributions are distinct from Medtronic's reported organic growth metrics, which explicitly exclude the impact of significant acquisitions from their current forecast [^][^]. While these deals are intended to foster organic contributions in future years, their direct impact on the Cardiovascular segment's organic growth rate in FY2027 is not specified as a current contributor [^][^][^].
The Cardiovascular segment is expected to show strong organic growth. Medtronic’s strategic cardiovascular-related investments aim to strengthen core franchises, digitize clinical workflows, and expand into high-growth adjacencies [^][^][^]. For fiscal year 2027, Medtronic has provided enterprise-wide organic revenue growth guidance of 6.75% to 7.25% [^][^][^]. Within this outlook, the Cardiovascular segment is anticipated to perform strongly, primarily bolstered by Cardiac Rhythm Management and renal denervation [^][^][^].
10. What Could Change the Odds
Key Catalysts
Medtronic provided overall company-wide guidance for fiscal year 2027 of 6.75% to 7.25% organic revenue growth [^] [^] [^] . This guidance includes a 53rd fiscal week benefit and contributions from the Diabetes business [^][^][^]. The 53rd fiscal week is estimated to contribute approximately 125 basis points to full-year organic growth and 500-600 basis points in the first quarter [^][^]. Key financial pressures for FY2027 include a $250 million total tariff impact on COGS, net interest expense headwinds, and the pending separation of the Diabetes business [^][^].
Management anticipates the cardiovascular segment's performance in fiscal 2027 will be broadly in line with fiscal 2026 performance [^] . The Cardiovascular segment achieved 10.1% organic revenue growth in fiscal 2026 [^][^]. Growth in this segment is supported by Cardiac Rhythm Management, renal denervation, and Cardiac Ablation Solutions (CAS) [^]. Catalysts include broadening physician demand for Affera and investments in ICE technologies to support future expansion of the cardiac ablation portfolio [^]. Affera milestones comprise VT-related breakthrough designation and continued global adoption of Sphere-9/Sphere-360 [^]. Medtronic completed the CathWorks acquisition, strengthening interventional cardiology and coronary disease diagnosis and treatment [^]. FDA approval for OmniaSecure in the left bundle branch area may support CRM/cardiovascular adoption. However, the available evidence does not disclose a separate cardiovascular segment organic growth rate for FY2027 [^][^][^][^][^][^]. Several cardiovascular catalysts are still early-stage, investigational, or pre-commercial [^][^][^][^][^][^].
Key Dates & Catalysts
- Expiration: August 31, 2027
- Closes: August 31, 2027
11. Decision-Flipping Events
- Trigger: Medtronic provided overall company-wide guidance for fiscal year 2027 of 6.75% to 7.25% organic revenue growth [^] [^] [^] .
- Trigger: This guidance includes a 53rd fiscal week benefit and contributions from the Diabetes business [^] [^] [^] .
- Trigger: The 53rd fiscal week is estimated to contribute approximately 125 basis points to full-year organic growth and 500-600 basis points in the first quarter [^] [^] .
- Trigger: Key financial pressures for FY2027 include a $250 million total tariff impact on COGS, net interest expense headwinds, and the pending separation of the Diabetes business [^] [^] .
13. Historical Resolutions
No historical resolution data available for this series.
